Bausch + Lomb Expands Glaucoma Treatment Portfolio

Bausch + Lomb Corporation (BLCO) has released an update.

Bausch + Lomb has acquired Elios Vision to enhance its glaucoma treatment capabilities with the innovative ELIOS procedure, which is minimally invasive and uses an excimer laser. This strategic move aims to integrate glaucoma treatment with cataract surgery, potentially transforming treatment standards for millions of patients globally.

For further insights into BLCO stock, check out TipRanks’ Stock Analysis page.